Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2022 / May / The Where and the How
Histology Histology Oncology

The Where and the How

For the first time, researchers have simultaneously assessed both spatial and activation information for proteins in FFPE tissue samples

By George Francis Lee 05/10/2022 News 1 min read

Share

To establish a cancer’s metastatic potential – and therefore the patient’s prognosis – it’s important to determine the activation status of proteins such as Rac and Cdc42. Unfortunately, existing methods offer either spatial information or activation status (via pulldown assay), but not both. To combat this, a novel detection technique specifically and rapidly identifies activated Rac and Cdc42 in FFPE tissue samples (1).

How does it work? Researchers at Hokkaido University’s Institute for Chemical Reaction Design and Discovery (WPI-ICReDD) developed molecular probes that bind specifically to activated Rac and Cdc24, then used non-contact agitation technology to speed up the binding reaction in FFPE tissue samples without negatively affecting the specimens or the quality of the staining. This approach avoids the loss of positional and heterogenicity information that takes place in pulldown assays, allowing the WPI-ICReDD team to analyze activation patterns in 50 colon cancer cases.

The results indicated that protein activity was concentrated at tumor invasive fronts and strongly corresponded with characteristics highlighted in TNM classification. In 29 of 33 tissue microarray samples, Rac/Cdc42 cell activity was higher in tumor cells than in regular colon mucosa. Increased Rac/Cdc42 activity was correlated with later disease stage and additional clinicopathologic factors such as venous and lymphatic vessel invasion.

First author Masumi Tsuda said, “This technology is effective for breast cancer and brain tumors as well as colorectal cancer, and it promises to provide useful information for predicting lymph node metastasis and for the assessment of Rac inhibitor-based therapies in the future (2).” The researchers expect their methodology to be useful in other small GTPases such as Ras, hopefully leading to personalized prognoses and more effective treatments.

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. M Tsuda et al., Sci Rep, 12, 1733 (2022). PMID: 35110666.
  2. Science Japan (2022). Available at: https://bit.ly/37DMQFq.

About the Author(s)

George Francis Lee

Interested in how disease interacts with our world. Writing stories covering subjects like politics, society, and climate change.

More Articles by George Francis Lee

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Your Newest Colleague?
Histology
Your Newest Colleague?

January 6, 2022

1 min read

The need for AI-based end-to-end biomarkers in oncology

Biospecimen Access For Biotechs
Histology
Biospecimen Access For Biotechs

February 14, 2022

1 min read

Quality, provenance, and “taking pot luck”

Case of the Month
Histology
Case of the Month

February 21, 2022

1 min read

The Art of the Laboratory
Histology
The Art of the Laboratory

March 25, 2022

1 min read

For the seventh time, we asked you to share the images you think capture the most beautiful, educational, or amusing aspects of pathology – and you delivered. Welcome to our gallery tour of the most visually striking discipline in medicine!

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.